Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)

Background Despite improvements in medical care, patients with advanced cancer still experience substantial symptom distress. There is increasing interest in the use of medicinal cannabinoids but little high-quality evidence to guide clinicians. This study aims to define the role of a 1:1 delta-9-te...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Current controlled trials in cardiovascular medicine Jg. 21; H. 1; S. 611 - 8
Hauptverfasser:	Hardy, Janet, Haywood, Alison, Gogna, Gauri, Martin, Jennifer, Yates, Patsy, Greer, Ristan, Good, Phillip
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London BioMed Central 06.07.2020 Springer Nature B.V BMC
Schlagworte:	Administration, Oral Biomedicine Cancer Cancer therapies Cannabidiol Cannabidiol - standards Cannabidiol - therapeutic use Cannabis Chemotherapy Collaboration Double-Blind Method Double-blind studies Dronabinol - standards Dronabinol - therapeutic use Drug dosages Health Sciences Humans Medicine Medicine & Public Health Multicenter Studies as Topic Multiple sclerosis Neoplasms - drug therapy Neoplasms - psychology Palliative care Palliative Care - methods Palliative Care - standards Patients Quality of Life Queensland Randomized Controlled Trials as Topic RCT Spasticity Statistics for Life Sciences Study Protocol Symptom control Syndrome Tetrahydrocannabinol THC Queensland Cannabis RCT Symptom control Palliative care Cannabidiol THC Cancer
ISSN:	1745-6215, 1745-6215
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!